BERKELEY, CA USA (Press Release) - May 15, 2013 -
Xofigo approved three months ahead of schedule under priority review program
Radium223 (Ra223) delivers high-energy radiation to osteoblastic metastasis of prostate cancer, resulting in irreparable double-stranded DNA damage. The effects of Ra223 on CD8+ T cell subsets in patients with prostate cancer is unknown.
Listen to Dr. Sartor from Tulane University present new data from the phase III ALSYMPCA trial (ALpharadin in SYMptomatic Prostate CAncer) in this podcast: "Radium-223 Chloride (Alpharadin) in Patients With Bone Metastases and Castration-Resistant Prostate Cancer (CRPC): A New Treatment Paradigm"
WHIPPANY, NJ USA (Press Release) - July 17, 2013 - Bayer HealthCare today announced that data from the pivotal Phase III ALSYMPCA (ALpharadin in SYMptomaticProstate CAncer) trial of its drug Xofigo® (radium Ra 223 dichloride) in castration-resistant prostate cancer (CRPC) patients with symptomatic bone metastases and no known visceral metastatic disease are published in the July 18 issue of the New England Journal of Medicine (NEJM).
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
